Laminin, a major component of basement membranes, is a large glycoprotein (Mr = 900 000) that promotes the adhesion, growth, migration, neurite outgrowth, differentiation and metastasis of a variety of cells (Martin and Timpl, 1987) . Laminin-1, the best characterised laminin, is composed of three chains, designated a-I (formerly A, Mr=400 000), 3-1 (formerly Bi, M =210 000) and y-l (formerly B2, M =200 000), which are assembled into a triple-stranded coiled-coil structure at the long arm (Burgeson et al., 1994) . The chains of laminin-1 have been cloned, sequenced Sasaki et al., , 1988 and attempts have been made to use such sequence data to define the active sites on laminin-I using synthetic peptides Iwamoto et al., 1988; Charonis et al., 1988; Kleinman et al., 1989; Tashiro et al., 1989 Tashiro et al., , 1991 Grant et al., 1989) . The YIGSR sequence located on the ,B-1 chain (positions [929] [930] [931] [932] [933] has been shown to promote cell adhesion, and migration and to inhibit angiogenesis Iwamoto et al., 1988; Grant et al., 1989; Sakamoto et al., 1991) . The peptide has also been shown to inhibit experimental metastasis and s.c. tumour growth (Iwamoto et al., , 1992b Kawasaki et al., 1991; Murata et al., 1989; Nakai et al., 1992; Sakamoto et al., 1991) . These findings suggest that the YIGSR peptide is a potential candidate for development of anti-cancer and antimetastatic agents.
Several modifications of YIGSR peptides have been reported to enhance the activity. Changes in the structure of the YIGSR sequence may be effective for the enhancement of its anti-tumour activity since the polymerised YIGSR peptide more effectively inhibits experimental metastasis than the monomeric peptide (Murata et al., 1989) . In addition, coupling to polyethylene glycol has also led to an increase in activity (Kawasaki et al., 1991) . Based on the conformational studies by NMR and computer modelling (Ostheimer et al., 1992 ) and the increased anti-tumour activity observed with the cyclic YIGSR , the turn structure of the YIGSR peptides has been suggested to be important for the activity. Based on these results, the multimeric YIGSR peptide (CH3CO-Tyr-lle-Gly-Ser-Arg-Gly)16-Lys8-Lys4-Lys2-Lys-Gly [(Ac-YIGSRG)16K8K4K2KG] (designated Ac-Y16) has been designed and its potentiated anti-tumour effect on mouse melanoma cells has been reported (Nomizu et al., 1993) . Moreover, the multimeric peptide has recently been reported to induce apoptosis in HT1080 human fibrosarcoma cells in vitro (Kim et al., 1994) . We report that a multimeric YIGSR peptide designated Ac-Y16 reduces the growth and experimental metastasis of HT1080 human fibrosarcoma cells. Our angiogenesis assay in vivo indicates that Ac-Y16 inhibits angiogenesis. It is likely that the antitumour effects of Ac-Y16 is a result of anti-angiogenic activity of Ac-Y16.
Materials and methods Materials
Peptides were synthesised as described previously (Nomizu et al., 1993) . Briefly, the linear peptides, Ac-YIGSR-NH2(Ac-Y1) and KLQSLDLSAAAQMTCGTPPGA (P4), were synthesised by the solid-phase method using an Applied Biosystems 431A automated peptide synthesiser on tertbutyloxycarbonyl strategy. Deprotection and cleavage from the resin were achieved by treatment with anhydrous hydrogen fluoride and the crude peptides were purified by reversed-phase high-performance liquid chromatography (HPLC). A multimeric form of YIGSR, was synthesised manually by the 9-fluorenylmethyloxycarbonyl (Fmoc) strategy on Wang-type resin (Fmoc-Gly-resin 0.1 mmol g-') using diisopropylcarbodiimide-N-hydroxybenzo- Received 4 April 1995; revised 12 October 1995; accepted 27 October trimethylsilylbromide-thioanisole in trifluoroacetic acid (0°C, 2 h) (Yajima et al., 1988) . The crude peptides were purified by reversed-phase HPLC. The identity of the peptides was confirmed by amino acid analysis.
Mouse laminin-1 was extracted and purified from the Engelbreth-Holm-Swarm (EHS) tumour, as described previously (Timpl et al., 1979) .
Matrigel, an extract of EHS tumour rich in basement membrane proteins (Kleinman et al., 1986) , was purchased from Becton Dickinson Labware (Bedford, MA, USA). The protein concentration of Matrigel used throughout the present study was 10 mg ml-'.
Animals and tumour Female 6-week-old Balb/c nu/nu mice were obtained from SLC (Shizuoka, Japan). Throughout the experiments, the mice were maintained in a laminar flow cabinet under specific pathogen-free conditions.
Female 5-week-old DDD mice were used to assess the effect of Ac-Y16 on the growth of Ehrlich solid and ascitic tumours. Ehrlich ascitic tumour cells (Kimura et al., 1980) , obtained from Dr S Taniguchi, Kyushu University, were maintained in the DDD mice and passaged routinely in ascites form. The mice were provided with food and water ad libitum.
Cells and culture HT1080 cells from a human fibrosarcoma (Rasheed et al., 1974) were maintained in Dulbecco's modified Eagle medium (DMEM) supplemented with 10% fetal calf serum (FCS), 100 units ml-' penicillin and 100 ig ml-' streptomycin (Gibco).
Cell adhesion assay Cell adhesion was assayed as described previously (Nomizu et al., 1992) . Briefly, various concentrations of either laminin-1 or peptides, which were dissolved in water were added to 96-well dishes (Immulon 2, Dynatech, Alexandria, VA, USA) and dried at room temperature overnight. The laminin-or peptide-coated wells were gently washed once with phosphate-buffered saline without Ca2+ and Mg2+ (PBS-) , and any uncoated surfaces were subsequently blocked with 0.1 ml of DMEM per well containing 1% heat-inactivated bovine serum albumin (BSA) for 1 h at 37°C. The solution was then removed gently, and HT1080 cells (5 x 104) were added to each well in a total volume of 0.1 ml of serum-free DMEM containing 0.2% BSA and incubated for 30 min at 37°C in 5% carbon dioxide/95% air. Wells were then washed with PBS-to remove unattached cells. Attached cells were stained with 0.1% crystal violet followed by measurement of optical density (OD) at 560 nm.
Inhibition assay
Inhibition of attachment to laminin-1 was assayed as previously described (Nomizu et al., 1992) . Ninety-six-well dishes (Immulon 2) were coated with laminin-l (1 pg per well) and blocked with DMEM and inactivated BSA as described above. Various amounts of peptides were mixed with HT1080 cells (5 x 104) and added to each well in a total volume of 0.1 ml. After incubation for 30 min, wells were washed with PBS-to remove unattached cells. Attached cells were counted as described above.
Lung tumour colonisation assay The inhibitory effect of the peptides on lung colonisation was assessed as described previously .
Versene-detached HT1080 cells (1 x 106) in 0.4 ml of minimum essential medium containing 0.5 mg of the synthetic peptide were injected into the tail veins of mice. Five mice were used for each group. Twenty-one days later, the mice were sacrificed. Lungs were removed, and the colonies that were visible over the whole lung surface were counted with the naked eye.
In another experiment, we examined the effect of i.p. administration of Ac-Y16 on lung colonisation. Versenedetached HT1080 cells (1 x 106) in 0.4 ml of minimum essential medium were injected into the tail veins of nude mice. Five mice per group were given Ac-Y16 i.p. once a day at a dose of 0.5 mg per mouse from day 3 to day 12 after the inoculation of HT1080 cells. Twenty-one days later the mice were sacrificed and the number of colonies over the whole lung surface was counted.
In vivo tumour angiogenesis assay Matrigel is a liquid at 4°C, but forms a solid gel immediately after implantation into the mice (Fridman et al., 1990; Iwamoto et al., 1991 Iwamoto et al., , 1992a Five mice per group were sacrificed on day 7 after the inoculation. The gel plugs were then removed together with the overlying skin and the underlying peritoneum, fixed in 10% buffered formalin for at least 24 h, cleared in Histoclear, embedded in paraffin, sectioned at 5mm thickness, deparaffinised, stained with Masson-Trichrome and processed for histological examination and image analysis. A computerised image analyser, Cosmozone program (NEC PC-9801, Tokyo, Japan), was used in order to quantitate the total area of neovessels. Histological slides stained with Masson-Trichrome stain were examined, adjusting the colour contrast to enhance the specifically stained vessels. The vascularised areas to be measured were chosen uniformly based on their proximity to the skeletal muscle-collagen interface from which the neovessels originated. Another five mice per group were sacrificed on day 14 after the inoculation. The gel plugs were removed and the anti-tumour effect of peptides was evaluated by weighing the tumour nodules grown in the gels. The presence of the tumour grown in the gel was histologically confirmed.
In another experiment, nude mice (ten mice per group) were each injected s.c. with 1 x 105 HT1080 cells mixed with 0.3 ml of Matrigel. Five mice per group were given peptides i.p. once a day at a dose of 0.5 mg per mouse for 5 days. The mice were then sacrificed on day 7 after tumour inoculation and angiogenesis was quantitated as described above. The remaining five mice per group were given peptides i.p. once a day at a dose of 0.5 mg per mouse for 10 days, sacrificed on day 14 after tumour inoculation and the tumours grown in the Matrigel were weighed as described above.
Treatment of mice bearing Ehrlich solid or ascitic tumours In order to rule out the direct cytotoxicity of Ac-Y16, the effect of Ac-Y16 on the growth of the ascitic tumours was compared with that on the growth of solid tumours. Ehrlich ascites tumour cells were suspended in PBS-at a rate of 5 x 107 cells ml-'. A 0.1 ml of the suspension mixed with 0.5 mg Ac-Y16 was inoculated s.c. near the abdominal midline or inoculated i.p. into a female DDD mouse. The mice were killed on day 9 or on day 14 after the inoculation. In mice bearing solid tumours, the tumours were removed and weighed immediately after death. In mice bearing ascites tumours, the ascites were collected and the number of ascites tumour cells was counted. (Figure 3c and d) . Co-injection of 0.5 mg per mouse of Ac-YI with the tumour cells reduced the total areas of neovessels to 60% of untreated controls. The inhibitory effect of Ac-Y16 on tumour angiogenesis was greater than that of Ac-Yl as the total area of neovessels was only 8% of untreated controls (Figure 3a) . When angiogenesis was assayed after daily i.p. injection of peptide in the same model, 0.5 mg of Ac-Y16 resulted in a 86% reduction in angiogenesis ( Figure  3b) . Weights of tumours determined on day 14 after tumour cell inoculation in the group given Ac-Y1 and Ac-Y16 were 91% and 24% respectively, relative to those in untreated mice (Table II Weights of the solid tumours determined on day 9 and on day 14 after the co-injection of Ac-Y16 (0.5 mg per mouse) with the tumour cells were only 9% and 6% of untreated controls respectively (Table III) . In contrast, when the tumours were grown i.p., as ascites, no significant difference could be detected between treated and control groups.
Discussion
The multimeric peptide Ac-Y16 was prepared by the multimeric antigen peptide (MAP) method developed by Tam (1988) , Tam and Lu (1989) , in which the branched core lysine structure is located in the interior of the molecule allowing many active YIGSR sequences on the surface to be accessible for interactions. Several sizes of multimeric YIGSR peptides, Ac-Y16, Ac-Y8, Ac-Y4, Ac-YI, were previously synthesised to explore the potentiation of the anti-tumour effect of the YIGSR peptides and consequently, the larger the peptide (Ac-Y16 > Ac-Y8 > Ac-Y4 > Ac-Y1), the more inhibitory effect there was on lung colonisation of B16-FIO melanoma cells (Nomizu et al., 1993) .
In the present study, we demonstrated that Ac-Y16 is active in the attachment of HT1080 cells, inhibits the attachment of the HT1080 cells to laminin, and reduces lung colonisation of HT1080 cells. These activities of Ac-Y16 were greater than those of the monomeric synthetic peptide Ac-YI. We speculate that Ac-YIGSR may inhibit experimental metastasis in part by competing with laminin for the laminin receptor on tumour cells and thus block the binding of the cells to the basement membranes.
It has been demonstrated that angiogenesis plays a critical role in tumour growth and metastasis (Fidler and Ellis, 1994) . The YIGSR sequence has been shown to prevent both the morphological differentiation of endothelial cells into capillary-like structures (Grant et al., 1989) and tumour angiogenesis by blocking the endothelial cell migration (Sakamoto et al., 1991) . Here, we used an in vivo assay, using the basement membrane extract, Matrigel, to determine the effect of Ac-Y16 and Ac-Yl on tumour angiogenesis. Coinjection with HT1080 cells of Ac-Y16 showed inhibition of both angiogenesis and growth of s.c. tumours. In addition, the extent of the inhibition by Ac-Y16 was greater than that by Ac-Y1 ( Figure 3 and Table II ). Intraperitoneal administration of 0.5 mg of Ac-Y16 per day was also effective in inhibiting angiogenesis, s.c. tumour growth and metastasis formation (Figure 3 , Tables I and II) . These results suggest:
(1) Ac-Y16 regulates the growth and the metastasis formation of HT1080 cells by its effect on angiogenesis; (2) the multimeric YIGSR peptide enhances the inhibitory effect on angiogenesis over that observed with the monomeric peptide; (3) both s.c. and i.p. injections of multimeric YIGSR peptides are effective.
The multimeric peptide has been reported to induce apoptosis in HT1080 human fibrosarcoma cells in vitro Ehrlich ascitic tumour cells suspended in PBS-were mixed with 0.5 mg of Ac-Y16 and then inoculated s.c. near the abdominal midline or inoculated i.p. into a female DDD mouse. The mice were killed on day 9 or on day 14 after inoculation. In mice bearing solid tumours, the tumours were removed and weighed immediately after death. In mice bearing ascitic tumours, the ascites were collected and the number of ascitic tumour (Kim et al., 1994) . However, no evidence indicating that Ac-Y16 induces apoptosis in vivo has been reported. The following data suggest that Ac-Y16 is not cytotoxic in vivo:
(1) Ac-Y16 significantly inhibited growth of Ehrlich solid tumour, but it did not affect ascitic tumour growth at all, even though the same cell source was used (Table III) ; (2) The histological examination of Matrigel removed on day 3 revealed that tumour cells co-injected with Matrigel and Ac-Y16 were viable, as observed in mouse inoculated with tumour cells alone; (3) Ac-Y16 was effective in blocking lung colonisation even if its administration was initiated on day 3 after i.v. inoculation of HT1080 cells when tumour cell attachment was supposed to have occurred (Table I) . Antitumour effects of Ac-Y16 are likely to result from antiangiogenesis as direct cytotoxicity on tumour cells was ruled out.
In order to metastasise, tumour cells must enter and then leave the circulatory system by crossing the barriers formed by the endothelium and basement membranes, and finally proliferate in the parenchymal tissue of the target organ (Liotta, 1984; Roos et al., 1979) . Our data suggest that the multimeric peptide, Ac-Y16, is effective in blocking tumour cell binding to basement membranes and inhibiting proliferation at the target organ of metastasis. These synergistic effects of Ac-Y16 suggest the potential usefulness of this compound for clinical applications in the treatment of metastasis.
